Lanova Medicines Limited

This study tests a new drug called LM-168, alone or with another drug toripalimab, in people with advanced solid tumours that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drug shrinks tumours. About 87 adults w…

This study tests whether a new drug combination (LM-108 plus toripalimab) works better than standard chemotherapy (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CCR8-positive). About 400 adults who have already tried …

This study tests a new drug called LM-24C5 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 49 adults will take part in this early-phase trial.

This study tests a new drug called LM-350 in about 80 adults with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the drug and be closely …

This study tests a new drug called LM-2417, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. About 320 adults ag…

This study tests a new drug called LM-24C5 combined with other cancer treatments for people with advanced solid tumors that have a specific protein (CEACAM5). About 130 adults whose cancer has returned or not responded to standard care will participate. The goal is to see if the …